To achieve this goal, the LOH levels of BRCA1/2-positive cancers in comparison to those bearing mutations in additional HR genes (HR+/BRCA1/2-), as well as the HR-negative samples, were calculated. The gene discussed is BRCA1; the disease is cancer.